Data analysis with Shapley values for automatic subject selection in Alzheimer’s disease data sets using interpretable machine learning

For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneou...

Full description

Saved in:
Bibliographic Details
Published inAlzheimer's research & therapy Vol. 13; no. 1; pp. 155 - 30
Main Authors Bloch, Louise, Friedrich, Christoph M.
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 15.09.2021
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification. An ML workflow was developed and trained for a subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation. The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set. The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE ε4 (ApoE ε4) alleles, cognitive test results, and volumetric MRI measurements.
AbstractList Background For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer’s disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification. Methods An ML workflow was developed and trained for a subset of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation. Results The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set. Conclusion The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE ε4 (ApoE ε4) alleles, cognitive test results, and volumetric MRI measurements.
Background For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification. Methods An ML workflow was developed and trained for a subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation. Results The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set. Conclusion The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE [epsilon]4 (ApoE [epsilon]4) alleles, cognitive test results, and volumetric MRI measurements. Keywords: Machine learning, Data Shapley, Interpretability, AIBL, ADNI, Shapley values, Mild cognitive impairment, Alzheimer's disease
For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification. An ML workflow was developed and trained for a subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation. The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set. The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE ε4 (ApoE ε4) alleles, cognitive test results, and volumetric MRI measurements.
Abstract Background For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer’s disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification. Methods An ML workflow was developed and trained for a subset of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation. Results The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set. Conclusion The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE ε4 (ApoE ε4) alleles, cognitive test results, and volumetric MRI measurements.
For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification. An ML workflow was developed and trained for a subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation. The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set. The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE [epsilon]4 (ApoE [epsilon]4) alleles, cognitive test results, and volumetric MRI measurements.
For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification.BACKGROUNDFor the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification.An ML workflow was developed and trained for a subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation.METHODSAn ML workflow was developed and trained for a subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation.The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set.RESULTSThe RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set.The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE ε4 (ApoE ε4) alleles, cognitive test results, and volumetric MRI measurements.CONCLUSIONThe Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE ε4 (ApoE ε4) alleles, cognitive test results, and volumetric MRI measurements.
ArticleNumber 155
Audience Academic
Author Friedrich, Christoph M.
Bloch, Louise
Author_xml – sequence: 1
  givenname: Louise
  orcidid: 0000-0001-7540-4980
  surname: Bloch
  fullname: Bloch, Louise
– sequence: 2
  givenname: Christoph M.
  orcidid: 0000-0001-7906-0038
  surname: Friedrich
  fullname: Friedrich, Christoph M.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34526114$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1u1TAQhSNURH_gBVggS0iITYqd2ImzQarKX6VKLIC1NXEmN75y4ovttCortjwCr8eT4PS20FshlMVE9jmfPeNzmO1NbsIse8roMWOyehVYyRqR04LllMq6yfmD7IDVQuYNa8q9O__72WEIa0qrqpD8UbZfclFUjPGD7McbiEBgAnsVTCCXJg7k0wAbi1fkAuyMgfTOE5ijGyEaTcLcrlFHEtCmYtxEzERO7LcBzYj-1_efgXQmIAQk3YIOGAOZg5lWSRjRbzxGaC2SEfRgJiQWwU9p-3H2sAcb8MlNPcq-vHv7-fRDfv7x_dnpyXmuRcNjjiXrsMemKFjVp9ZApyJ0S6loWy5LlAUv6qaWZVNRzqkoRdVozQUUmlGg5VF2tuV2DtZq480I_ko5MOp6wfmVAp86taiERGwL0bFaVlygAJSialsGrOkqxrvEer1lbeZ2xE7jFD3YHejuzmQGtXIXSnLOKyYT4OUNwLuvadhRjSZotBYmdHNQhahLXopGLPd-fk-6drNPD3et4ryUktV_VStIDZipd-lcvUDVSVVLmloRTVId_0OVvg5Ho1PKepPWdwwv7hgGBBuH4Oy8BCDsCp_dncifUdwmLgnkVqC9C8Fjr7SJsHDSFYxVjKol3GobbpXCra7DrRZrcc96S_-P6Tfvmfx8
CitedBy_id crossref_primary_10_3390_diagnostics15050612
crossref_primary_10_1007_s11306_022_01937_0
crossref_primary_10_1016_j_compbiomed_2024_108029
crossref_primary_10_1007_s42979_022_01371_y
crossref_primary_10_3389_fpubh_2022_940182
crossref_primary_10_1016_j_jstrokecerebrovasdis_2023_107354
crossref_primary_10_3233_JAD_220776
crossref_primary_10_3390_neurolint16060098
crossref_primary_10_3390_jpm14080811
crossref_primary_10_1186_s12938_023_01107_w
crossref_primary_10_1007_s42600_024_00394_z
crossref_primary_10_1021_jasms_3c00403
crossref_primary_10_1016_j_drudis_2024_104280
crossref_primary_10_1007_s12559_023_10153_4
crossref_primary_10_1007_s11682_025_00984_0
crossref_primary_10_3389_fcvm_2024_1419551
crossref_primary_10_1038_s41598_024_82544_y
crossref_primary_10_1186_s12911_024_02556_6
crossref_primary_10_1016_j_bbe_2022_06_007
crossref_primary_10_3390_jpm12040550
crossref_primary_10_1177_15333175241275215
crossref_primary_10_3389_fnagi_2025_1542514
crossref_primary_10_3390_s24155024
crossref_primary_10_1186_s12958_024_01271_1
crossref_primary_10_1371_journal_pone_0285416
crossref_primary_10_3390_s22187037
crossref_primary_10_2196_68066
crossref_primary_10_3390_diagnostics14182049
crossref_primary_10_3390_jpm12010043
Cites_doi 10.1038/nrneurol.2009.215
10.1002/hbm.20934
10.1023/A:1010933404324
10.1007/BF00994018
10.1016/j.neurobiolaging.2003.12.007
10.1016/j.media.2020.101694
10.1212/WNL.34.7.939
10.5220/0010211300870099
10.1186/s13195-018-0455-y
10.1162/jocn.2009.21407
10.1111/j.1365-2796.2004.01380.x
10.1073/pnas.90.5.1977
10.1109/ICDM.2008.17
10.1016/j.jalz.2016.10.006
10.3389/fnagi.2019.00220
10.2307/3001968
10.1145/335191.335388
10.1016/j.neuroimage.2015.01.048
10.1021/ci0342472
10.1159/000320988
10.1186/s13195-020-00716-0
10.1038/srep46263
10.1212/01.WNL.0000110315.26026.EF
10.1186/s12916-018-1122-7
10.1093/brain/awaa137
10.1159/000072920
10.1016/j.dadm.2015.11.002
10.1002/jmri.21049
10.1214/aoms/1177730491
10.1136/gpsych-2018-100005
10.1136/bmj.b158
10.1101/2019.12.12.874784
10.1109/ACCESS.2019.2932769
10.1016/j.ins.2017.11.036
10.1007/978-3-319-47578-3
10.1007/s10548-012-0246-x
10.1016/j.pscychresns.2011.06.014
10.1002/widm.1379
10.1186/s13024-018-0299-8
10.1145/2939672.2939785
10.1109/CVPR.2017.369
10.1016/j.neuroimage.2018.08.042
10.1515/9781400881970-018
10.1016/S0896-6273(02)00569-X
10.2307/1268249
10.1002/hbm.25398
10.1007/s11263-015-0816-y
10.1038/s41598-018-29295-9
10.1067/mhj.2002.123579
10.1016/j.neuroimage.2006.01.021
10.1613/jair.1.12125
10.1002/alz.12068
10.1109/IJCNN.2011.6033571
10.1038/s41598-021-87762-2
10.1016/j.neuroimage.2004.03.040
10.1016/j.neuroimage.2012.01.021
10.1016/j.jalz.2011.03.003
10.1126/science.8346443
10.1007/s11682-018-9831-2
10.1007/s13167-020-00216-z
10.1038/nature14539
10.1016/j.neuroimage.2012.02.084
10.18653/v1/n16-3020
10.1212/WNL.0b013e3181cb3e25
10.1136/jnnp.2010.231555
10.1145/2950109
10.1007/978-3-319-59050-912
10.3233/JAD-170261
10.1109/CVPR.2016.90
10.1017/S1041610209009405
10.1038/srep45269
10.1371/journal.pone.0066367
10.1371/journal.pone.0236868
10.1016/j.dadm.2018.07.004
10.1016/j.jalz.2010.03.004
ContentType Journal Article
Copyright 2021. The Author(s).
COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: 2021. The Author(s).
– notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
CorporateAuthor for the Alzheimer’s Disease Neuroimaging Initiative
Alzheimer’s Disease Neuroimaging Initiative
CorporateAuthor_xml – name: for the Alzheimer’s Disease Neuroimaging Initiative
– name: Alzheimer’s Disease Neuroimaging Initiative
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13195-021-00879-4
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

MEDLINE



MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
EISSN 1758-9193
EndPage 30
ExternalDocumentID oai_doaj_org_article_58eeb25d178645e5ae856bb1a19d614d
PMC8444618
A678017859
34526114
10_1186_s13195_021_00879_4
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations Australia
Germany
GeographicLocations_xml – name: Australia
– name: Germany
GrantInformation_xml – fundername: CIHR
– fundername: NIA NIH HHS
  grantid: U01 AG024904
GroupedDBID ---
0R~
23M
2WC
53G
5VS
6J9
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFS
ACIHN
ACJQM
ACUHS
ADBBV
ADUKV
AEAQA
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
DIK
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HZ~
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M~E
O5R
O5S
O9-
OK1
P2P
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c594t-e31defe92216f193ac6f15cb005bb483e82427978396044053569cc45a2c10a03
IEDL.DBID 7X7
ISSN 1758-9193
IngestDate Wed Aug 27 01:30:54 EDT 2025
Thu Aug 21 17:38:06 EDT 2025
Fri Jul 11 07:44:12 EDT 2025
Fri Jul 25 04:23:24 EDT 2025
Tue Jun 17 21:15:26 EDT 2025
Tue Jun 10 20:37:34 EDT 2025
Thu May 22 21:15:47 EDT 2025
Mon Jul 21 06:00:44 EDT 2025
Tue Jul 01 02:38:51 EDT 2025
Thu Apr 24 23:00:13 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords ADNI
Shapley values
Alzheimer’s disease
Interpretability
Mild cognitive impairment
Machine learning
AIBL
Data Shapley
Language English
License 2021. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c594t-e31defe92216f193ac6f15cb005bb483e82427978396044053569cc45a2c10a03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-7540-4980
0000-0001-7906-0038
OpenAccessLink https://www.proquest.com/docview/2574438817?pq-origsite=%requestingapplication%
PMID 34526114
PQID 2574438817
PQPubID 2040174
PageCount 30
ParticipantIDs doaj_primary_oai_doaj_org_article_58eeb25d178645e5ae856bb1a19d614d
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8444618
proquest_miscellaneous_2573435950
proquest_journals_2574438817
gale_infotracmisc_A678017859
gale_infotracacademiconefile_A678017859
gale_healthsolutions_A678017859
pubmed_primary_34526114
crossref_citationtrail_10_1186_s13195_021_00879_4
crossref_primary_10_1186_s13195_021_00879_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-09-15
PublicationDateYYYYMMDD 2021-09-15
PublicationDate_xml – month: 09
  year: 2021
  text: 2021-09-15
  day: 15
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Alzheimer's research & therapy
PublicationTitleAlternate Alzheimers Res Ther
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References 879_CR14
SM Lundberg (879_CR44) 2017
CC Aggarwal (879_CR16) 2017
M Kusy (879_CR26) 2018; 430-431
G Van Rossum (879_CR40) 2009
B Winblad (879_CR47) 2004; 256
C Birkenbihl (879_CR78) 2020; 11
879_CR19
C Patterson (879_CR2) 2018
879_CR18
O Russakovsky (879_CR33) 2015; 115
DL Beekley (879_CR88) 2004; 18
J Cao (879_CR3) 2018; 13
B Duraisamy (879_CR25) 2018; 13
S Tang (879_CR37) 2021; 11
I Arevalo-Rodriguez (879_CR71) 2015; 3
T Schlegl (879_CR22) 2017
G Stiglic (879_CR83) 2020; 10
F Wilcoxon (879_CR49) 1945; 1
EE Bron (879_CR82) 2015; 111
MW Weiner (879_CR53) 2017; 13
DM Hawkins (879_CR13) 2004; 44
CG Northcutt (879_CR32) 2021; 70
RD Cook (879_CR41) 1977; 19
LS Elias-Sonnenschein (879_CR70) 2011; 82
KA Ellis (879_CR45) 2009; 21
M Dlugaj (879_CR85) 2010; 30
T Jo (879_CR9) 2019; 11
LS Shapley (879_CR36) 1953
O Pelka (879_CR79) 2020; 15
A Schmermund (879_CR86) 2002; 144
879_CR23
L An (879_CR30) 2017; 7
SP Poulin (879_CR64) 2011; 194
cr-split#-879_CR15.1
879_CR20
H Yang (879_CR72) 2019; 32
cr-split#-879_CR15.2
H Wang (879_CR24) 2019; 7
RS Desikan (879_CR55) 2006; 31
C Cortes (879_CR31) 1995; 20
F Pedregosa (879_CR59) 2011; 12
E Lawrence (879_CR77) 2017; 59
Alzheimer’s Association (879_CR1) 2020; 16
A Burns (879_CR5) 2009; 338
879_CR34
B Fischl (879_CR56) 2002; 33
S Qiu (879_CR80) 2020; 143
WJ Strittmatter (879_CR69) 1993; 90
CR Jack Jr. (879_CR51) 2008; 27
E Corder (879_CR68) 1993; 261
RC Petersen (879_CR27) 2010; 74
C Ledig (879_CR67) 2018; 8
C D’Urso (879_CR17) 2016; 7
Y LeCun (879_CR35) 2015; 521
879_CR39
879_CR38
D Ferreira (879_CR11) 2017; 7
DS Marcus (879_CR87) 2010; 22
L Breiman (879_CR42) 2001; 45
H Fröhlich (879_CR76) 2018; 16
E Pellegrini (879_CR8) 2018; 10
M Reuter (879_CR57) 2012; 61
E Westman (879_CR58) 2012; 26
Y Zhang (879_CR66) 2013; 8
T Chen (879_CR43) 2016
CR Jack (879_CR74) 2004; 62
879_CR84
M Dadar (879_CR12) 2021; 42
H Tabatabaei-Jafari (879_CR65) 2015; 1
CR Jack (879_CR52) 2010; 6
PM Thompson (879_CR73) 2004; 22
RA Sperling (879_CR4) 2011; 7
SG Mueller (879_CR62) 2010; 31
HB Mann (879_CR50) 1947; 18
D Shigemizu (879_CR6) 2020; 12
879_CR48
B Fischl (879_CR54) 2012; 62
M Ribeiro (879_CR60) 2016
L deToledo-Morrell (879_CR63) 2004; 25
3C study group (879_CR28) 2003; 22
E Adeli-Mosabbeb (879_CR29) 2015
GB Frisoni (879_CR61) 2010; 6
G Devi (879_CR10) 2018; 10
cr-split#-879_CR21.2
J Samper-González (879_CR75) 2018; 183
cr-split#-879_CR21.1
879_CR81
G McKhann (879_CR46) 1984; 34
J Wen (879_CR7) 2020; 63
References_xml – volume: 6
  start-page: 67
  issue: 2
  year: 2010
  ident: 879_CR61
  publication-title: Nat Rev Neurol
  doi: 10.1038/nrneurol.2009.215
– volume: 31
  start-page: 1339
  issue: 9
  year: 2010
  ident: 879_CR62
  publication-title: Hum Brain Mapp
  doi: 10.1002/hbm.20934
– volume-title: World Alzheimer Report 2018 - The State of the Art of Dementia Research: New Frontiers
  year: 2018
  ident: 879_CR2
– volume: 45
  start-page: 5
  issue: 1
  year: 2001
  ident: 879_CR42
  publication-title: Mach Learn
  doi: 10.1023/A:1010933404324
– volume: 20
  start-page: 273
  issue: 3
  year: 1995
  ident: 879_CR31
  publication-title: Mach Learn
  doi: 10.1007/BF00994018
– volume: 25
  start-page: 1197
  issue: 9
  year: 2004
  ident: 879_CR63
  publication-title: Neurobiol Aging
  doi: 10.1016/j.neurobiolaging.2003.12.007
– volume: 63
  start-page: 101694
  year: 2020
  ident: 879_CR7
  publication-title: Med Image Anal
  doi: 10.1016/j.media.2020.101694
– volume: 34
  start-page: 939
  issue: 7
  year: 1984
  ident: 879_CR46
  publication-title: Neurology
  doi: 10.1212/WNL.34.7.939
– ident: 879_CR39
  doi: 10.5220/0010211300870099
– volume: 10
  start-page: 122
  issue: 1
  year: 2018
  ident: 879_CR10
  publication-title: Alzheimers Res Ther
  doi: 10.1186/s13195-018-0455-y
– volume: 22
  start-page: 2677
  issue: 12
  year: 2010
  ident: 879_CR87
  publication-title: J Cogn Neurosci
  doi: 10.1162/jocn.2009.21407
– volume: 256
  start-page: 240
  issue: 3
  year: 2004
  ident: 879_CR47
  publication-title: J Intern Med
  doi: 10.1111/j.1365-2796.2004.01380.x
– volume: 90
  start-page: 1977
  issue: 5
  year: 1993
  ident: 879_CR69
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.90.5.1977
– ident: 879_CR18
  doi: 10.1109/ICDM.2008.17
– volume: 13
  start-page: 561
  issue: 5
  year: 2017
  ident: 879_CR53
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2016.10.006
– volume: 11
  start-page: 220
  year: 2019
  ident: 879_CR9
  publication-title: Front Aging Neurosci
  doi: 10.3389/fnagi.2019.00220
– volume: 1
  start-page: 80
  issue: 6
  year: 1945
  ident: 879_CR49
  publication-title: Biometrics
  doi: 10.2307/3001968
– ident: 879_CR20
  doi: 10.1145/335191.335388
– volume-title: Advances in Neural Information Processing Systems (NIPS 2015): 7-12 December 2015; Montreal, Canada
  year: 2015
  ident: 879_CR29
– ident: #cr-split#-879_CR15.2
– ident: 879_CR81
– volume: 111
  start-page: 562
  year: 2015
  ident: 879_CR82
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2015.01.048
– volume: 44
  start-page: 1
  issue: 1
  year: 2004
  ident: 879_CR13
  publication-title: J Chem Inf Comput Sci
  doi: 10.1021/ci0342472
– volume: 30
  start-page: 362
  issue: 4
  year: 2010
  ident: 879_CR85
  publication-title: Dement. Geriatr Cogn Disord
  doi: 10.1159/000320988
– volume: 12
  start-page: 145
  issue: 1
  year: 2020
  ident: 879_CR6
  publication-title: Alzheimers Res Ther
  doi: 10.1186/s13195-020-00716-0
– volume: 7
  start-page: 46263
  issue: 1
  year: 2017
  ident: 879_CR11
  publication-title: Sci Rep
  doi: 10.1038/srep46263
– volume: 62
  start-page: 591
  issue: 4
  year: 2004
  ident: 879_CR74
  publication-title: Neurology
  doi: 10.1212/01.WNL.0000110315.26026.EF
– volume: 16
  start-page: 150
  issue: 1
  year: 2018
  ident: 879_CR76
  publication-title: BMC Med
  doi: 10.1186/s12916-018-1122-7
– volume: 143
  start-page: 1920
  issue: 6
  year: 2020
  ident: 879_CR80
  publication-title: Brain
  doi: 10.1093/brain/awaa137
– ident: 879_CR19
– volume: 22
  start-page: 316
  issue: 6
  year: 2003
  ident: 879_CR28
  publication-title: Neuroepidemiology
  doi: 10.1159/000072920
– volume-title: Advances in Neural Information Processing Systems (NIPS 2017): 4-9 December 2017; Long Beach, California, US
  year: 2017
  ident: 879_CR44
– volume: 1
  start-page: 487
  issue: 4
  year: 2015
  ident: 879_CR65
  publication-title: Alzheimers Dement (Amst)
  doi: 10.1016/j.dadm.2015.11.002
– volume: 27
  start-page: 685
  issue: 4
  year: 2008
  ident: 879_CR51
  publication-title: J Magn Reson Imaging
  doi: 10.1002/jmri.21049
– ident: #cr-split#-879_CR21.1
– volume: 18
  start-page: 50
  issue: 1
  year: 1947
  ident: 879_CR50
  publication-title: Ann Math Stat
  doi: 10.1214/aoms/1177730491
– volume: 32
  start-page: e100005
  issue: 2
  year: 2019
  ident: 879_CR72
  publication-title: Gen Psychiatr
  doi: 10.1136/gpsych-2018-100005
– volume: 338
  start-page: 467
  year: 2009
  ident: 879_CR5
  publication-title: BMJ
  doi: 10.1136/bmj.b158
– ident: 879_CR84
  doi: 10.1101/2019.12.12.874784
– volume: 7
  start-page: 107964
  year: 2019
  ident: 879_CR24
  publication-title: IEEE Access
  doi: 10.1109/ACCESS.2019.2932769
– volume: 430-431
  start-page: 65
  year: 2018
  ident: 879_CR26
  publication-title: Inf Sci (N Y)
  doi: 10.1016/j.ins.2017.11.036
– volume-title: Outlier analysis
  year: 2017
  ident: 879_CR16
  doi: 10.1007/978-3-319-47578-3
– volume: 26
  start-page: 9
  issue: 1
  year: 2012
  ident: 879_CR58
  publication-title: Brain Topogr
  doi: 10.1007/s10548-012-0246-x
– volume: 3
  start-page: CD010783
  year: 2015
  ident: 879_CR71
  publication-title: Cochrane Database Syst Rev
– volume: 194
  start-page: 7
  issue: 1
  year: 2011
  ident: 879_CR64
  publication-title: Psychiatry Res Neuroimaging
  doi: 10.1016/j.pscychresns.2011.06.014
– ident: #cr-split#-879_CR15.1
– volume: 10
  start-page: 1379
  issue: 5
  year: 2020
  ident: 879_CR83
  publication-title: WIREs Data Min Knowl Disc
  doi: 10.1002/widm.1379
– volume: 13
  start-page: 64
  issue: 1
  year: 2018
  ident: 879_CR3
  publication-title: Mol Neurodegener
  doi: 10.1186/s13024-018-0299-8
– volume-title: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD 2016): 13-17 August 2016; San Francisco, California, US
  year: 2016
  ident: 879_CR43
  doi: 10.1145/2939672.2939785
– ident: 879_CR38
  doi: 10.1109/CVPR.2017.369
– volume: 183
  start-page: 504
  year: 2018
  ident: 879_CR75
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2018.08.042
– volume-title: Contributions to the Theory of Games
  year: 1953
  ident: 879_CR36
  doi: 10.1515/9781400881970-018
– volume: 33
  start-page: 341
  issue: 3
  year: 2002
  ident: 879_CR56
  publication-title: Neuron
  doi: 10.1016/S0896-6273(02)00569-X
– volume: 19
  start-page: 15
  issue: 1
  year: 1977
  ident: 879_CR41
  publication-title: Technometrics
  doi: 10.2307/1268249
– volume: 42
  start-page: 2734
  issue: 9
  year: 2021
  ident: 879_CR12
  publication-title: Hum Brain Mapp
  doi: 10.1002/hbm.25398
– volume: 115
  start-page: 211
  issue: 3
  year: 2015
  ident: 879_CR33
  publication-title: Int J Comput Vis
  doi: 10.1007/s11263-015-0816-y
– volume: 8
  start-page: 11258
  issue: 1
  year: 2018
  ident: 879_CR67
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-29295-9
– volume: 144
  start-page: 212
  issue: 2
  year: 2002
  ident: 879_CR86
  publication-title: Am Heart J
  doi: 10.1067/mhj.2002.123579
– volume: 31
  start-page: 968
  issue: 3
  year: 2006
  ident: 879_CR55
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2006.01.021
– volume: 70
  start-page: 1373
  year: 2021
  ident: 879_CR32
  publication-title: J Artif Intell Res
  doi: 10.1613/jair.1.12125
– volume: 16
  start-page: 391
  issue: 3
  year: 2020
  ident: 879_CR1
  publication-title: Alzheimers Dement
  doi: 10.1002/alz.12068
– ident: #cr-split#-879_CR21.2
– volume: 18
  start-page: 270
  issue: 4
  year: 2004
  ident: 879_CR88
  publication-title: Alzheimer Dis Assoc Disord
– ident: 879_CR14
  doi: 10.1109/IJCNN.2011.6033571
– volume: 11
  start-page: 8366
  issue: 1
  year: 2021
  ident: 879_CR37
  publication-title: Sci Rep
  doi: 10.1038/s41598-021-87762-2
– volume: 12
  start-page: 2825
  year: 2011
  ident: 879_CR59
  publication-title: J Mach Learn Res
– volume: 22
  start-page: 1754
  issue: 4
  year: 2004
  ident: 879_CR73
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2004.03.040
– volume: 62
  start-page: 774
  issue: 2
  year: 2012
  ident: 879_CR54
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2012.01.021
– volume: 7
  start-page: 280
  issue: 3
  year: 2011
  ident: 879_CR4
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2011.03.003
– volume: 261
  start-page: 921
  issue: 5123
  year: 1993
  ident: 879_CR68
  publication-title: Science
  doi: 10.1126/science.8346443
– volume: 13
  start-page: 87
  issue: 1
  year: 2018
  ident: 879_CR25
  publication-title: Brain Imaging Behav
  doi: 10.1007/s11682-018-9831-2
– volume: 11
  start-page: 367
  issue: 3
  year: 2020
  ident: 879_CR78
  publication-title: EPMA J
  doi: 10.1007/s13167-020-00216-z
– volume: 521
  start-page: 436
  issue: 7553
  year: 2015
  ident: 879_CR35
  publication-title: Nature
  doi: 10.1038/nature14539
– volume: 61
  start-page: 1402
  issue: 4
  year: 2012
  ident: 879_CR57
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2012.02.084
– volume-title: Proceedings of the 2016 Conference of the North American Chapter of the Association for Computational Linguistics: Demonstrations (NAACL 2016): 12-17 June 2016; San Diego, California, US
  year: 2016
  ident: 879_CR60
  doi: 10.18653/v1/n16-3020
– volume: 74
  start-page: 201
  issue: 3
  year: 2010
  ident: 879_CR27
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e3181cb3e25
– volume-title: Python 3 Reference Manual
  year: 2009
  ident: 879_CR40
– volume: 82
  start-page: 1149
  issue: 10
  year: 2011
  ident: 879_CR70
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp.2010.231555
– volume: 7
  start-page: 14
  issue: 3
  year: 2016
  ident: 879_CR17
  publication-title: ACM J Data Inf Qual
  doi: 10.1145/2950109
– volume-title: Proceedings of the Information Processing in Medical Imaging (IPMI 2017): 25-30 June 2017: Boone, North Carolina, US
  year: 2017
  ident: 879_CR22
  doi: 10.1007/978-3-319-59050-912
– volume: 59
  start-page: 1359
  issue: 4
  year: 2017
  ident: 879_CR77
  publication-title: J Alzheimers Dis
  doi: 10.3233/JAD-170261
– ident: 879_CR34
  doi: 10.1109/CVPR.2016.90
– volume: 21
  start-page: 672
  issue: 4
  year: 2009
  ident: 879_CR45
  publication-title: Int Psychogeriatr
  doi: 10.1017/S1041610209009405
– ident: 879_CR23
– volume: 7
  start-page: 45269
  issue: 1
  year: 2017
  ident: 879_CR30
  publication-title: Sci Rep
  doi: 10.1038/srep45269
– volume: 8
  start-page: 1
  issue: 6
  year: 2013
  ident: 879_CR66
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0066367
– volume: 15
  start-page: 1
  issue: 9
  year: 2020
  ident: 879_CR79
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0236868
– volume: 10
  start-page: 519
  issue: 1
  year: 2018
  ident: 879_CR8
  publication-title: Alzheimers Dement (Amst)
  doi: 10.1016/j.dadm.2018.07.004
– volume: 6
  start-page: 212
  issue: 3
  year: 2010
  ident: 879_CR52
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2010.03.004
– ident: 879_CR48
SSID ssj0066284
Score 2.4387574
Snippet For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will...
Background For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will...
Abstract Background For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI)...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 155
SubjectTerms ADNI
AIBL
Alzheimer Disease - diagnostic imaging
Alzheimer Disease - genetics
Alzheimer's disease
Australia
Biomarkers
Classification
Cognitive ability
Cognitive Dysfunction - diagnostic imaging
Computer-aided medical diagnosis
Data Analysis
Data mining
Data Shapley
Datasets
Dementia
Diagnosis
Discriminant analysis
Game theory
Humans
Interpretability
Machine Learning
Magnetic Resonance Imaging
Methods
Neural networks
Noise
Older people
Shapley values
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQT70gEAUCpRgJiQOKGie2Yx-3QFUhwQUq9WbZjtNdaZutmuyFE1cegdfjSZhxvNFGSHDhtNJ6Im3mf7wz3xDyWiFKua1t3rRM5Lxp61xDGp-Xrat5y4OtLM47f_osLy75xytxtbfqC3vCRnjgkXGnQgUo_kTDaiW5CMIGJaRzzDLdQGhp0PtCzNsVU6MPlhK87m5ERsnTnlUsTiJD6VyoWud8FoYiWv-fPnkvKM0bJvci0PkDcj-ljnQx_uSH5F7oHpEf7-1gqU3QIhSvVemXpb0FW6cI5B16CmkptdthE8FZab91ePVC-7gAB6RCVx1drL8tw-om3P36_rOn6U8bit2jQDf0FLvjr-lqalB060BvYhtmoGnvxPURuTz_8PXdRZ7WK-ReaD7koWJNaIMuSyZbyOOshw_h0S6dAxEGBeG7xqshBHDhCAQjtfdc2NKzwhbVY3LQbbrwlNDGO-llKFwlHYeCUjeldErZUlZONYXLCNtx2_iEPY4rMNYm1iBKmlFCBiRkooQMz8jb6ZnbEXnjr9RnKMSJElGz4xegSybpkvmXLmXkJaqAGUdQJ9s3C4jo4LmU0Bl5EynQ-uEFvE1DDMAGxNGaUR7PKMFq_fx4p2YmeY3egPvkvFKK1Rl5NR3jk9gJ14XNNtJUHKepi4w8GbVyeukK98VDgZuReqavM67MT7rVMmKKK865ZOrZ_2Djc3JYRlPTORPH5GC424YXkLoN7iRa6W8tw0Jp
  priority: 102
  providerName: Directory of Open Access Journals
Title Data analysis with Shapley values for automatic subject selection in Alzheimer’s disease data sets using interpretable machine learning
URI https://www.ncbi.nlm.nih.gov/pubmed/34526114
https://www.proquest.com/docview/2574438817
https://www.proquest.com/docview/2573435950
https://pubmed.ncbi.nlm.nih.gov/PMC8444618
https://doaj.org/article/58eeb25d178645e5ae856bb1a19d614d
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NjtMwELZg98IFgfgLLMVISBxQtHFiO84JdcuuVkisELBSb5btuNtK3bQ06YUTVx6B1-NJmHHdsBHSnqLGE6nx_HhmMvMNIW8UopSb0qT1jImU17MyrcCNT_OZLfmMe1MY7Hf-dCHPL_nHqZjGhFsbyyr3NjEY6nrlMEd-DKLFeaEUK9-vv6c4NQq_rsYRGnfJIUKXYUlXOe0DLinB9u4bZZQ8blnBQj8yBNCZKquUDw6jgNn_v2W-cTQNyyZvnENnD8j96EDS8Y7jD8kd3zwivz6YzlATAUYoJlfp17lZg8ZThPP2LQXnlJpttwoQrbTdWkzA0DaMwQHe0EVDx8sfc7-49ps_P3-3NH66oVhDCnRdS7FG_oou-jJFu_T0OhRjehqnT1w9Jpdnp98m52kcspA6UfEu9QWr_cxXec7kDLw54-AiHGqntcBIr-AQLzFBhDAuHOFgZOUcFyZ3LDNZ8YQcNKvGPyO0dlY66TNbSMshrKzqXFqlTC4Lq-rMJoTtd1u7iECOgzCWOkQiSuodhzRwSAcOaZ6Qd_0z6x3-xq3UJ8jEnhKxs8ON1eZKR1XUQnlvc1GzUkkuvDBeCWktM6yqwVmpE_IKRUDvGlF7C6DHcK6D_VKiSsjbQIE2AF7AmdjKANuAaFoDyqMBJeiuGy7vxUxH29Hqf5KekNf9Mj6J9XCNX20DTcGxpzpLyNOdVPYvXeDUeAhzE1IO5HWwK8OVZjEPyOKKcy6Zen7733pB7uVBiaqUiSNy0G22_iW4Zp0dBf0bkcOT04vPX-DXRE5GIc3xFw5YPUA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELbK9gAXBOIvUKiRQBxQ1HViO84BoS1ttaXtCkEr9WbsxPsjbbPLZlcITlx5BF6Ch-JJmHGSpRFSbz2tFE9WiWf8ecaZ-YaQFwpZyk1iwnzIRMjzYRKm4MaH0dAmfMidiQ3WO58MZP-Mvz8X5xvkd1MLg2mVDSZ6oM5nGZ6R74BpcR4rxZK38y8hdo3Cr6tNC43KLI7ct68QspVvDvdAvy-j6GD_9F0_rLsKhJlI-TJ0Mcvd0KVRxOQQ3BeTwY_ARvXCWnhyp2DXSvBEBHlLOPKfyDTLuDBRxrqmG8P_3iCbPIZQpkM2d_cHHz422C8loH1TmqPkTsli5iugIWTvqiQNeWv7810C_t8LLm2G7UTNSzvfwR1yu3ZZaa-ysbtkwxX3yM89szTU1JQmFI9z6aexmQPGUCQQdyUFd5ia1XLmSWFpubJ45ENL33gHrIFOCtqbfh-7yYVb_Pnxq6T1xyKKWasgtywpZuWP6GSdGGmnjl749E9H634Xo_vk7FoU8IB0ilnhHhGaZ1Zm0nVtLC2HQDbNI2mVMpGMrcq7NiCsmW2d1Zzn2Hpjqn3so6SuNKRBQ9prSPOAvF7fM68YP66U3kUlriWRrdtfmC1Gul78WijnbCRylijJhRPGKSGtZYalObhHeUC20QR0Vfq6xhzdA08CEFOJNCCvvASiDrxAZuriCZgG5O9qSW61JAEtsvZwY2a6RqtS_1tbAXm-HsY7MQOvcLOVl4k5VnF3A_Kwssr1S8fYpx4C64AkLXttzUp7pJiMPZe54pxLph5f_Vjb5Gb_9ORYHx8Ojp6QW5FfUGnIxBbpLBcr9xQcw6V9Vq9GSj5fNwD8BT6Rdes
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Data+analysis+with+Shapley+values+for+automatic+subject+selection+in+Alzheimer%E2%80%99s+disease+data+sets+using+interpretable+machine+learning&rft.jtitle=Alzheimer%27s+research+%26+therapy&rft.au=Bloch%2C+Louise&rft.au=Friedrich%2C+Christoph+M&rft.au=the+Alzheimer%E2%80%99s+Disease+Neuroimaging+Initiative&rft.date=2021-09-15&rft.pub=BioMed+Central&rft.eissn=1758-9193&rft.volume=13&rft.spage=1&rft_id=info:doi/10.1186%2Fs13195-021-00879-4
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1758-9193&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1758-9193&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1758-9193&client=summon